Search / Trial NCT00000368

Treatment of Panic Disorder: Long Term Strategies

Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE · Nov 2, 1999

Trial Information

Current as of December 27, 2024

Completed

Keywords

Adult Cognitive Behavioral Therapy Pharmacotherapy Long Term Treatment Remission And Relapse Male Panic Disorder Paroxetine Serotonin Uptake Inhibitors Panic Disorder *Therapy Panic Disorder Drug Therapy Paroxetine *Therapeutic Use Serotonin Uptake Inhibitors *Therapeutic Use

ClinConnect Summary

To determine if maintenance CBT produces a more sustained improvement among patients with panic disorder (PD) who respond to an initial course of cognitive behavior therapy (CBT) alone. For those who do not respond sufficiently to CBT alone, to determine if the addition of pharmacotherapy is acceptable and if this improves response among those inadequate responders to CBT alone.

This multicenter study builds upon the findings of a prior study comparing imipramine, placebo, CBT, and their combination in the treatment of PD patients with no more than mild agoraphobia. That study found respon...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - primary diagnosis of Panic disorder with or without Agoraphobia (all levels of agoraphobia are included).
  • Exclusion Criteria:
  • current substance abuse or dependence,
  • current active suicidal potential;
  • any history of psychosis, bipolar disorder (I or II) or cyclothymia;
  • pending application or existing medical disability claim;
  • significant cognitive impairment,
  • current uncontrolled general medical illness requiring intervention,
  • psychotherapy directed at anxiety or panic which will not be discontinued by the first treatment visit, and daily use of 2mg of Xanax or equivalent.
  • Exclusion criteria for paroxetine study:
  • hypersensitivity to Selective Serotonin Reuptake Inhibitors (SSRI),
  • pregnancy, lactation, or planned pregnancy during the course of the study,
  • contemporaneous medication that may interfere or interact with paroxetine,
  • prior treatment with therapeutic doses of paroxetine (40mg/d for 1 mo),
  • concurrent treatment with antidepressants.

Trial Officials

Katherine H. Shear, MD

Study Chair

University of Pittsburgh

David H Barlow, PhD

Principal Investigator

Boston University Department of Psychology

Jack Gorman, MD

Principal Investigator

Columbia University School of Medicine

Scott Woods, MD

Principal Investigator

Yale University

About New York State Psychiatric Institute

The New York State Psychiatric Institute (NYSPI) is a leading research organization dedicated to advancing the understanding and treatment of mental health disorders. Affiliated with Columbia University, NYSPI integrates clinical research with cutting-edge scientific inquiry to develop innovative therapeutic strategies and improve patient care. With a focus on a wide range of psychiatric conditions, NYSPI conducts clinical trials that aim to translate findings from laboratory research into effective interventions, enhancing the quality of life for individuals affected by mental illness. Committed to ethical research practices and collaboration, NYSPI plays a pivotal role in shaping the future of psychiatric care through rigorous scientific exploration and community engagement.

Locations

New Haven, Connecticut, United States

Boston, Massachusetts, United States

New York, New York, United States

Pittsburgh, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials